Liquidia Corp
NASDAQ:LQDA

Watchlist Manager
Liquidia Corp Logo
Liquidia Corp
NASDAQ:LQDA
Watchlist
Price: 15.09 USD -0.98% Market Closed
Market Cap: 1.3B USD

Liquidia Corp
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Liquidia Corp
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Liquidia Corp
NASDAQ:LQDA
Tax Provision
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Tax Provision
-$2.6B
CAGR 3-Years
-24%
CAGR 5-Years
-3%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Tax Provision
-$554m
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
-5%
Pfizer Inc
NYSE:PFE
Tax Provision
$28m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Tax Provision
-$2.8B
CAGR 3-Years
-23%
CAGR 5-Years
-12%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Tax Provision
-$2.1B
CAGR 3-Years
-54%
CAGR 5-Years
-27%
CAGR 10-Years
-13%

Liquidia Corp
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.

LQDA Intrinsic Value
11.01 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Liquidia Corp's Tax Provision?
Tax Provision
0 USD

Based on the financial report for Dec 31, 2024, Liquidia Corp's Tax Provision amounts to 0 USD.

Back to Top